Degarelix Vs. Leuprolide In Patients With Advanced Prostate Cancer

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON(R) (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment.